IFPMA Covid-19 Günlük Bülteni – 6 Mayıs

06.05.2020

Top news:

  • CEPI calls for another round of proposals inviting organizations around the world to apply for funding to speed up development, scale-up manufacturing capacity, and expand the geographical footprint of production of COVID-19 vaccine candidates.
  • New draft landscape of COVID-19 candidate vaccines published by WHO: 8 candidate vaccines in clinical evaluation & 100 candidate vaccines in preclinical evaluation
  • Novartis & partner Incyte will take Jakafi into a second late-stage trial for COVID-19 patients with acute respiratory distress syndrome (ARDS).
  • Eli Lilly and Chinese drug maker Shanghai Junshi Biosciences Co. collaborate on new antibody therapies for COVID-19 & Pfizer and New York University are partnering on a vaccine.
  • Sanofi said it plans to enrol thousands of subjects globally for trials of its vaccine candidate with GSK and that it has started to discuss advanced purchases with several countries.
  • Millions are predicted to develop and die of tuberculosis as result of COVID-19, setting off global efforts to end TB by 5-8 years.

ACCESS & IP

MANUFACTURING & SUPPLY

COVID-19 vaccines & treatments

  • Pipeline Review: CEPI seeks to expand COVID-19 vaccine portfolio, focusing on speed and global manufacturing.CEPI calls for Proposals inviting organizations around the world to apply for funding to speed up development, scale-up manufacturing capacity, and expand the geographical footprint of production of COVID-19 vaccine candidates.
  • FT Health: We’re not all in this together. Three questions to Seth Berkley, head of Gavi, on the impact of COVID-19 and vaccine R&D. “In developing countries, we need some type of global access agreement, which will be tough in this political environment. Plus we need to be prepared to manufacture “at risk”. If we can get a prioritised list of approaches, we can begin to ensure adequate production.” Several references to the articles from the special report on Combatting Coronavirus are made.
  • BioPharma: Lonza and Moderna shoot for billion COVID-19 vaccine doses. Moderna announced it has partnered with Lonza with the aim of producing one billion doses annually.
  • Bloomberg:  Gilead Under Gun to Mass-Produce Virus Drug or Risk Exclusivity.  Gilead has patent exclusivity on its potential COVID-19 treatment remdesivir for the next 15 years, but the company could be forced to license its patents if the drug is approved and it can’t keep up with production demand.

Other

GLOBAL ECONOMIC IMPACT

Europe

Asia

Africa

GLOBAL HEALTH IMPACT

VACCINE/ TREATMENT DEVELOPMENT

IFPMA members

Others

DIAGNOSTICS

CLINICAL TRIALS

  • Reuters: Sanofi to enrol thousands for its coronavirus vaccine trials.  Sanofi said it plans to enrol thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GSK and that it has started to discuss advanced purchases with several countries.
  • Fierce Pharma: Regeneron eyes human tests of COVID-19 antibody cocktail in June. Regeneron’s planning to test the antibody cocktail in three different clinical programs, R&D chief George Yancopoulos explained. First, it will study the drug as a prophylactic measure to prevent infection in individuals at high risk. Second, it plans to use it in mild patients who are sent home after diagnosis, to see whether the therapy can cut the risk of their being hospitalized. Thirdly, it wants to evaluate whether the antibody cocktail can improve clinical outcomes in hospitalized patients.

DONATIONS

COVID-19 & EARNINGS

WHO – COVID-19 UPDATE, 6 May

Statement at the media briefing of Dr Tedros here.

  • Today, WHO, UNICEF and the International Federation of the Red Cross have published guidance for countries on how to maintain community-based health care in the context of COVID-19.
  • As more and more countries consider how to ease so-called lockdown restrictions, I want to reiterate the six criteria that WHO recommends countries consider:
    • First, that surveillance is strong, cases are declining and transmission is controlled;
    • Second, that health system capacities are in place to detect, isolate, test and treat every case and trace every contact;
    • Third, that outbreak risks are minimized in special settings like health facilities and nursing homes;
    • Fourth, that preventive measures are in place in workplaces, schools and other places where it’s essential for people to go;
    • Fifth, that importation risks can be managed;
    • And sixth, that communities are fully educated, engaged and empowered to adjust to the “new norm”.
  • The risk of returning to lockdown remains very real if countries do not manage the transition extremely carefully, and in a phased approach.

WHO: DRAFT landscape of COVID-19 candidate vaccines – 5 May 2020.

  • 8 candidate vaccines in clinical evaluation
  • 100 candidate vaccines in preclinical evaluation

WHO: Community-based health care, including outreach and campaigns,in the context of the COVID-19 pandemic. The guide includes practical recommendations for countries on sustaining essential services at the community level, leveraging community health workers for the response to COVID-19 while keeping them safe, and advice for how to adapt services for specific diseases and age groups.